🔴 Lantern Pharma is trading 5% down today with no clear company-specific catalyst identified

Lantern Pharma is trading 5.02% down at $0.70 on October 13, 2026, with no clear company-specific announcement identified to explain the decline.

• Its latest identified trial update was Taiwan approval for the next stage of its Phase 2 HARMONIC trial, reported October 7.
• XBI was down 2.01% in the supplied market context and may be adding sector pressure.
• Lantern is scheduled to present its Open-Medicine AI platform at 12:30 p.m. ET; no source links the presentation to the decline.